Zafbena™: A New Generation Bendamustine Formulation Utilizing Captisol Technology

[Article Title]

Zafbena™ is the third generation of bendamustine formulation, designed to address the limitations of previous products and improve patient care in hematologic malignancies. Earlier bendamustine products, such as Treanda® and Bendeka®, have been widely used in clinical practice but present challenges including short dosing solution stability, long injection times, and contraindications related to excipients.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.